{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:23:04Z","timestamp":1784204584888,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jiangsu Key Medical Talents Fund","award":["ZDRCB20160003"],"award-info":[{"award-number":["ZDRCB20160003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to explore the prognostic value of baseline metabolic parameters of <jats:sup>18<\/jats:sup>F-FDG PET\/CT imaging in patients with angioimmunoblastic T-cell lymphoma (AITL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Fifty-six AITL patients (average age 64.0\u2009\u00b1\u20091.3\u00a0years) diagnosed pathologically from August 2009 to August 2019 were enrolled in this retrospective study. The total metabolic tumour volume (TMTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax), and correlated clinical characteristics were collected and analysed. TMTV was computed with the 41% SUVmax threshold method. The chi-square test or Fisher\u2019s exact probability method was used to compare clinical characteristics. Kaplan\u2013Meier curves were used to describe progression-free survival (PFS) and overall survival (OS). The log-rank test was used to analyse the difference within groups. The statistically significant factors in the univariate regression analysis were incorporated into the Cox risk proportional regression model for multivariate survival analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The TMTV cut-off value was 514.6\u00a0cm<jats:sup>3<\/jats:sup> from the ROC curve analysis. Forty (71.4%) patients progressed and 31 (55.4%) patients died within a median follow-up time of 19.1 (interquartile range 7.8\u201334.6) months. The 1-year and 3-year PFS rates were 42.9% and 30.1%, and the 3-year and 5-year OS rates were 45.9% and 34.4%, respectively. Univariate survival analysis showed that high TMTV and TLG may be the factors contributing to poor PFS and OS. Multivariate analysis showed that TMTV and prognostic index for T-cell lymphoma (PIT) were independent parameters for PFS and OS in AITL patients. TMTV, combined with PIT, may have better risk stratification performance than TMTV alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Baseline TMTV and PIT were independent prognostic predictors in AITL patients. The combination of TMTV and PIT can facilitate prognostic stratification and contribute to personalized therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-021-00807-5","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T11:02:58Z","timestamp":1626346978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic value of baseline total metabolic tumour volume of 18F-FDG PET\/CT imaging in patients with angioimmunoblastic T-cell lymphoma"],"prefix":"10.1186","volume":"11","author":[{"given":"Huanyu","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiannv","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5802-094X","authenticated-orcid":false,"given":"Chongyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"issue":"2","key":"807_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31(2):240\u20136.","journal-title":"J Clin Oncol"},{"issue":"10","key":"807_CR2","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","volume":"34","author":"S Chiba","year":"2020","unstructured":"Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia. 2020;34(10):2592\u2013606.","journal-title":"Leukemia"},{"issue":"9","key":"807_CR3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","volume":"129","author":"MA Lunning","year":"2017","unstructured":"Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095\u2013102.","journal-title":"Blood"},{"issue":"1","key":"807_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/ejh.13239","volume":"103","author":"E Crickx","year":"2019","unstructured":"Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L, et al. Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. Eur J Haematol. 2019;103(1):35\u201342.","journal-title":"Eur J Haematol"},{"issue":"7","key":"807_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","volume":"92","author":"JO Armitage","year":"2017","unstructured":"Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017;92(7):706\u201315.","journal-title":"Am J Hematol"},{"issue":"12","key":"807_CR6","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1080\/10428194.2018.1459610","volume":"59","author":"H Hong","year":"2018","unstructured":"Hong H, Fang X, Wang Z, Huang H, Lam ST, Li F, et al. Angioimmunoblastic T-cell lymphoma: a prognostic model from a retrospective study. Leuk Lymphoma. 2018;59(12):2911\u20136.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"807_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.seminhematol.2013.11.008","volume":"51","author":"K Mosalpuria","year":"2014","unstructured":"Mosalpuria K, Bociek RG, Vose JM. Angioimmunoblastic T-cell lymphoma management. Semin Hematol. 2014;51(1):52\u20138.","journal-title":"Semin Hematol"},{"issue":"Suppl 1","key":"807_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington SF, Kluge R. FDG PET for therapy monitoring in hodgkin and non-hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97\u2013110.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"807_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/joim.12813","volume":"284","author":"TC El-Galaly","year":"2018","unstructured":"El-Galaly TC, Villa D, Gormsen LC, Baech J, Lo A, Cheah CY. FDG-PET\/CT in the management of lymphomas: current status and future directions. J Intern Med. 2018;284(4):358\u201376.","journal-title":"J Intern Med"},{"issue":"27","key":"807_CR10","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048\u201358.","journal-title":"J Clin Oncol"},{"issue":"7","key":"807_CR11","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1080\/10428194.2016.1253834","volume":"58","author":"D Shao","year":"2017","unstructured":"Shao D, Gao Q, Liang CH, Wang SX. Discussion of 18F-FDG PET\/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 2017;58(7):1581\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"807_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"10","key":"807_CR13","doi-asserted-by":"publisher","first-page":"e0140830","DOI":"10.1371\/journal.pone.0140830","volume":"10","author":"S Kanoun","year":"2015","unstructured":"Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, et al. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in hodgkin lymphoma. PLoS ONE. 2015;10(10):e0140830.","journal-title":"PLoS ONE"},{"issue":"2","key":"807_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol I. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol I"},{"issue":"27","key":"807_CR15","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"23","key":"807_CR16","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.7150\/jca.30415","volume":"10","author":"J Xia","year":"2019","unstructured":"Xia J, Zhu HY, Liang JH, Ding CY, Wang L, Wu W, et al. The prognostic role of 18F-FDG PET\/CT baseline quantitative metabolic parameters in peripheral T-cell lymphoma. J Cancer. 2019;10(23):5805\u201311.","journal-title":"J Cancer"},{"issue":"15","key":"807_CR17","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1002\/cam4.3226","volume":"9","author":"A Kitadate","year":"2020","unstructured":"Kitadate A, Narita K, Fukumoto K, Terao T, Tsushima T, Kobayashi H, et al. Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma. Cancer Med. 2020;9(15):5509\u201318.","journal-title":"Cancer Med"},{"key":"807_CR18","first-page":"9746716","volume":"2020","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhang X, Qin H, Zhao Z, Li J, Zhang B, et al. Prognostic values of baseline (18)F-FDG PET\/CT in patients with peripheral T-cell lymphoma. Biomed Res Int. 2020;2020:9746716.","journal-title":"Biomed Res Int"},{"key":"807_CR19","first-page":"4502489","volume":"2020","author":"H Wang","year":"2020","unstructured":"Wang H, Yu W, Wu T, Xue Y, Zhang D, Xu H. The incremental prognostic value of baseline (18)F-FDG PET\/CT imaging in angioimmunoblastic T-cell lymphoma. Biomed Res Int. 2020;2020:4502489.","journal-title":"Biomed Res Int"},{"key":"807_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","volume":"15","author":"SH Jung","year":"2015","unstructured":"Jung SH, Ahn JS, Kim YK, Kweon SS, Min JJ, Bom HS, et al. Prognostic significance of interim PET\/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer. 2015;15:198.","journal-title":"BMC Cancer"},{"issue":"3","key":"807_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/hon.2697","volume":"38","author":"C Schmitz","year":"2020","unstructured":"Schmitz C, Rekowski J, M\u00fcller SP, Hertenstein B, Franzius C, Ganser A, et al. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: a subgroup analysis of the PETAL trial. Hematol Oncol. 2020;38(3):244\u201356.","journal-title":"Hematol Oncol"},{"issue":"1","key":"807_CR22","doi-asserted-by":"publisher","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","volume":"14","author":"B Guo","year":"2019","unstructured":"Guo B, Tan X, Ke Q, Cen H. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis. PLoS ONE. 2019;14(1):e0210224.","journal-title":"PLoS ONE"},{"key":"807_CR23","doi-asserted-by":"crossref","unstructured":"Feng X, Wen X, Li L, Sun Z, Li X, Zhang L, et al. Baseline total metabolic tumor volume and total lesion glycolysis measured on 18F-FDG PET-CT predict outcomes in T-cell lymphoblastic lymphoma. Cancer Res Treat. 2020.","DOI":"10.4143\/crt.2020.123"},{"issue":"1","key":"807_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-020-00698-y","volume":"10","author":"C Jiang","year":"2020","unstructured":"Jiang C, Teng Y, Chen J, Wang Z, Zhou Z, Ding C, et al. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL). Ejnmmi Res. 2020;10(1):110.","journal-title":"Ejnmmi Res"},{"issue":"4","key":"807_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdw011","volume":"27","author":"AS Cottereau","year":"2016","unstructured":"Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27(4):719\u201324.","journal-title":"Ann Oncol"},{"issue":"8","key":"807_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41389-020-00259-x","volume":"9","author":"R Mhaidly","year":"2020","unstructured":"Mhaidly R, Krug A, Gaulard P, Lemonnier F, Ricci JE, Verhoeyen E. New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. Oncogenesis. 2020;9(8):73.","journal-title":"Oncogenesis"},{"issue":"1","key":"807_CR27","doi-asserted-by":"publisher","first-page":"12907","DOI":"10.1038\/s41598-018-31212-z","volume":"8","author":"Y Shang","year":"2018","unstructured":"Shang Y, Fu X, Chang Y, Li Y, Zhang M. B2 microglobulin is a novel prognostic marker of angioimmunoblastic T-cell lymphoma. Sci Rep. 2018;8(1):12907.","journal-title":"Sci Rep"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00807-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-021-00807-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-021-00807-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T11:27:08Z","timestamp":1626348428000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-021-00807-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s13550-021-00807-5","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}